SGLT 2 inhibitors provide kidney, cardiovascular benefits for diabetes patients

Published On 2021-11-13 09:29 GMT | Update On 2021-11-13 09:29 GMT

In addition to lowering blood sugar levels, diabetes drugs called Sodium-glucose cotransporter 2 (SGLT2) inhibitors can provide kidney- and cardiovascular-related benefits for people with type 2 diabetes.

A recent study has found that such benefits are also experienced by individuals with type 1 diabetes. There is a significant risk reductions for cardiovascular disease and kidney failure with SGLT2 inhibitor treatment in type 1 diabetes, confirms study.

For more details, check out the full story on the link

SGLT2 Inhibitors May Protect Kidney And Heart In Adults With Type 1 Diabetes: Study

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SGLT 2 inhibitors provide kidney, cardiovascular benefits for diabetes patients

Similar News

A Diabetes Drug May Maintain Kidney Health: Study Finds

Kidney Stones: Pushing Fragments Could Be Key to Reducing Recurrence Risk, Study Reveals

Randomised Trial Finds Low-Impact Exercise and Yoga Effective for Managing Urinary Incontinence

Higher Thiazide Doses May Help Prevent Kidney Stones: JAMA finds

Dialysis May Not Be Optimal for All Older Adults with Kidney Failure, Study Reveals

LENS trial a first of its kind large scale trial shows striking 27% reduction in diabetic retinopathy progression

Study Finds No Increased Risk for Transplant Patients from Donor Kidneys with Toxoplasma

Study shows SGLT2i or Finerenone Added to RAAS Inhibitors Offers Kidney and Heart Protection for Diabetics with CKD